First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Neoplasms, Prostate
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 54 (planned)
- Started
- Feb 10, 2026
- Main results expected
- Mar 24, 2028
- Fully finished
- Mar 26, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose limiting toxicities (DLTs)
Measured over: 28 days
Number of participants with adverse events (AEs), and serious adverse events (SAEs)
Measured over: Approximately 45 months
Number of participants with adverse events (AEs), and serious adverse events (SAEs) by Severity
Measured over: Approximately 45 months
Number of participants with AEs leading to dose modifications
Measured over: Approximately 45 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["statusModule"]}
Trial ID NCT07332455 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC